Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Pru p 3 is a 9 kDa nonspecific lipid transfer protein (nsLTP) that serves as the primary allergen in peaches (*Prunus persica*). In Mediterranean populations, it is a major sensitizer responsible for severe food-allergic reactions, including anaphylaxis. As a therapeutic agent, Pru p 3 is utilized in allergen-specific immunotherapy (AIT), particularly via sublingual administration (SLIT), to induce clinical desensitization and long-term immune tolerance. The mechanism of action involves modulating the immune system toward a tolerogenic profile, characterized by epigenetic modifications such as DNA methylation changes in dendritic cells (DCs). These alterations regulate the expression of genes involved in T cell activation, antigen presentation, and inflammatory signaling, including HLA-DQA1, HLA-DQB1, FOXP1, and MTOR.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Pru p 3.